HIV
India, Sweden and The Netherlands form HIV/AIDS research partnership
May 22, 2018Manufacturing and Production, Research and Development AIDS, HIV, India, Sweden, The Netherlands, pharma
A first-of-its-kind collaboration has been announced by the governments of India, Sweden and The Netherlands with the goal of advancing …
ViiV’s two-drug regimen gets EU approval for HIV-1
May 22, 2018Manufacturing and Production, Sales and Marketing EMA, EU, Europe, HIV, Juluca, ViiV Healthcare, pharma
ViiV Healthcare has announced that its HIV therapy Juluca (dolutegravir/rilpivirine) has been awarded marketing authorisation in the EU from the …
Startup CEO who injected untested herpes cure during live stream found dead
May 2, 2018Research and Development Aaron Traywick, Ascendance Biomedical, HIV, herpes, pharma
Aaron Traywick, the 28-year-old CEO of biotech startup Ascendance Biomedical who made headlines when he injected himself with an untested …
Top Ten most popular articles on Pharmafile.com this week
March 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Celgene, EMA, Gilead, HIV, Herceptin, Japan, NHS, Ontruzant, Sanofi, opioid crisis, opioids, pharma, real world data, top ten, zinbryta
After a particularly jarring bout of cold weather and snow, we may just have seen off the worst of winter …
FDA greenlights alternative therapy for multidrug-resistant HIV patients
March 7, 2018Research and Development, Sales and Marketing HIV, Theratechnologies, Trogarzo, pharma
Theratechnologies has revealed that Trogarzo has received approval from the FDA as a treatment of HIV-1 in patients with multidrug-resistant …
Switching to Gilead’s Biktarvy proves non-inferior in HIV patients
March 6, 2018Manufacturing and Production, Research and Development Biktarvy, Gilead, HIV, pharma
Gilead has unveiled findings from two Phase 3 studies into the efficacy of switching to its three-drug combo Biktarvy (bictegravir/emtricitabine/tenofovir …
Gilead investigational data gives hope for HIV eradication in humans
March 5, 2018Research and Development, Sales and Marketing Gilead, HIV, pharma
Gilead has lifted the curtain on new preclinical data on the efficacy of a combo therapy of GS-9620, its investigational …
FDA approves Gilead’s Biktarvy for HIV as Viiv Healthcare launches patent lawsuit
February 8, 2018Sales and Marketing Biktarvy, FDA, GSK, Gilead, HIV, Pfizer, Shionogi, US, ViiV Healthcare, descovy, pharma
Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.
Top Ten most popular articles on Pharmafile.com this week
January 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, HIV, J&J, JJ, Johnson & Johnson, Pfizer, Shire, Teva, Xarelto, patient reported outcomes
The Xmas break is now a distant memory as we move further into January, and with another Friday comes another …
AIDS charity lambasts “ethically challenged” Gilead over price hikes
January 11, 2018Sales and Marketing AIDS, Gilead, HIV, Truvada, biotech, drugs, pharma, pharmaceutical
The AIDS Healthcare Foundation (AHF) has strongly criticised Gilead prices increases across the board for its HIV and AIDS treatment, …
Slow-release, once-weekly pill for HIV developed
January 10, 2018Research and Development HIV, Lyndra, biotech, drugs, pharma, pharmaceutical
Patient adherence is a big issue across the healthcare system, where individuals, even with the most serious conditions, do not …
The global HIV/AIDS movement
November 27, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AIDS, HIV, International HIV/AIDS Alliance
Increasingly collaborative efforts have seen the threat of HIV recede and brought hope to demographics and communities most vulnerable to …
Learning lessons from HIV to change the treatment access landscape
November 23, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, HIV, pharma
Greg Alton, Executive Vice President of Corporate and Medical Affairs at Gilead, reveals how the rapid development and distribution of …
FDA approves first-ever two-drug HIV regimen, GSK’s Juluca
November 22, 2017Research and Development, Sales and Marketing AIDS, FDA, GSK, Gilead, GlaxoSmithKilne, HIV, Juluca, ViiV Healthcare, pharma
GlaxoSmithKline has announced that the FDA has awarded US marketing authorisation to the first two-drug regimen in the treatment of …
Partnerships hold the key to making HIV history
November 20, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, Janssen, pharma
Brian Woodfall, Global Head of Late Development, Infectious Diseases at Janssen, explains why a future without HIV can only be …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
